Can Intellia Therapeutics Turn Exciting Trial Results into Profits?
Shares of gene-editing pioneer Intellia Therapeutics (NASDAQ: NTLA) have burst higher in response to the most exciting clinical trial results the biotech industry has produced in a long time. It's still early, but it looks like the company found a way to edit troublesome genes on the fly.
Until now, experimental CRISPR-based therapies have been used to edit the genetic code contained in stem cells after they've been harvested from patients. Intellia employed the technology that underpins COVID-19 vaccines from Moderna and BioNTech to design a potential cure for a rare inherited disease, and can probably make more such cures.
Image source: Getty Images.
Source Fool.com
